• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Baxter International Inc.

    11/19/25 5:17:33 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care
    Get the next $BAX alert in real time by email
    FWP 1 baxter-2025bondsxfwp.htm FWP Document

    Filed Pursuant to Rule 433
    Free Writing Prospectus dated November 19, 2025
    Relating to Preliminary Prospectus dated November 19, 2025
    Registration Statement No. 333-285217
    baxterlogoa.jpg
    PRICING TERM SHEET
    Issuer:
    Baxter International Inc.
    Title of Designated Securities:
    4.450% Senior Notes due 2029 (the “2029 Notes”)
    4.900% Senior Notes due 2030 (the “2030 Notes”)
    5.650% Senior Notes due 2035 (the “2035 Notes”)
    Ratings (Moody’s / S&P)*:
    Baa3 (stable) / BBB- (stable)
    Format:
    SEC Registered
    Ranking:
    2029 Notes: Senior unsecured
    2030 Notes: Senior unsecured
    2035 Notes: Senior unsecured
    Offering Size:
    2029 Notes: $300,000,000
    2030 Notes: $700,000,000
    2035 Notes: $1,000,000,000
    Trade Date:
    November 19, 2025
    Settlement Date**:
    December 4, 2025 (T+10)
    Maturity Date:
    2029 Notes: February 15, 2029
    2030 Notes: December 15, 2030
    2035 Notes: December 15, 2035
    Interest Rate:
    2029 Notes: 4.450%
    2030 Notes: 4.900%
    2035 Notes: 5.650%
    Interest Rate Adjustment:
    The interest rate payable on each series of the Notes may be increased if either Moody’s Investors Service, Inc. (“Moody’s”) or S&P Global Ratings (“S&P”) (or, in each case, a substitute rating agency therefor), downgrades the debt rating applicable to such Notes.
    Issue Price to Public:
    2029 Notes: 99.932% of the principal amount
    2030 Notes: 99.826% of the principal amount
    2035 Notes: 99.899% of the principal amount
    In each case, plus accrued interest, if any, from December 4, 2025


    2
    Interest Payment Dates:
    2029 Notes: Semi-annually on each February 15 and August 15, commencing on February 15, 2026
    2030 Notes: Semi-annually on each June 15 and December 15, commencing on June 15, 2026
    2035 Notes: Semi-annually on each June 15 and December 15, commencing on June 15, 2026
    Benchmark Treasury:
    2029 Notes: 3.500% UST due November 15, 2028
    2030 Notes: 3.625% UST due October 31, 2030
    2035 Notes: 4.000% UST due November 15, 2035
    Benchmark Treasury Price / Yield:
    2029 Notes: 99-25 ¼ / 3.575%
    2030 Notes: 99-22 ¾ / 3.689%
    2035 Notes: 99-02 + / 4.113%
    Spread to Benchmark Treasury:
    2029 Notes: +90 bps
    2030 Notes: +125 bps
    2035 Notes: +155 bps
    Yield to Maturity:
    2029 Notes: 4.475%
    2030 Notes: 4.939%
    2035 Notes: 5.663%
    Day Count Basis:
    30/360
    Optional Redemption:
    2029 Notes: Following issuance and prior to January 15, 2029, make-whole +15 bps. At any time on or after January 15, 2029, par call
    2030 Notes: Following issuance and prior to November 15, 2030, make-whole +20 bps. At any time on or after November 15, 2030, par call
    2035 Notes: Following issuance and prior to September 15, 2035, make-whole +25 bps. At any time on or after September 15, 2035, par call
    Minimum Denomination:$2,000 x $1,000
    CUSIP / ISIN:
    2029 Notes: 071813 DC0 / US071813DC01
    2030 Notes: 071813 DD8 / US071813DD83
    2035 Notes: 071813 DE6 / US071813DE66
    Settlement and Trading:
    Through the facilities of The Depository Trust Company
    Governing Law:
    New York Law
    Joint Book-Running Managers:
    Citigroup Global Markets Inc.
    BofA Securities, Inc.
    J.P. Morgan Securities LLC
    Deutsche Bank Securities Inc.
    Goldman Sachs & Co. LLC
    Morgan Stanley & Co. LLC
    2

    3
    Co-Managers:
    HSBC Securities (USA) Inc.
    Mizuho Securities USA LLC
    Scotia Capital (USA) Inc.
    SG Americas Securities, LLC
    TD Securities (USA) LLC
    U.S. Bancorp Investments, Inc.
    Wells Fargo Securities, LLC
    Academy Securities, Inc.
    Independence Point Securities LLC
    Loop Capital Markets LLC
    MUFG Securities Americas Inc.
    R. Seelaus & Co., LLC
    * Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.
    ** Under Rule 15c6-1 of the U.S. Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes prior to the business day immediately before the Settlement Date will be required, by virtue of the fact that the Notes initially settle in T+10, to specify alternative settlement arrangements at the time of any such trade to prevent a failed settlement.
    Changes from Preliminary Prospectus Supplement
    The Preliminary Prospectus Supplement is hereby updated to reflect the following changes:
    The Company expects to increase the Maximum Cash Spent in the Concurrent 2027 Notes Tender Offer from $300 million to $600 million and use the additional net proceeds to repurchase any 2027 Notes validly tendered and not validly withdrawn.
    Nothing herein should be construed as an offer to purchase or a solicitation of an offer to purchase any of the Company’s 2027 Notes. The Concurrent 2027 Notes Tender Offer is being made only upon the terms and conditions set forth in the Offer to Purchase.
    The Issuer has filed a registration statement (including a prospectus) and a preliminary prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it. In the case of Citigroup Global Markets Inc., you may request the prospectus by contacting Citigroup Global Markets Inc. toll-free at 1-800-831-9146; in the case of BofA Securities, Inc., you may request the prospectus by contacting BofA Securities, Inc. toll-free at 1-800-294-1322; in the case of J.P. Morgan Securities LLC, you may request the prospectus by contacting J.P. Morgan Securities LLC collect at 1-212-834-4533.
    The information in this pricing term sheet supplements the preliminary prospectus supplement and the accompanying prospectus, and supersedes the information in the preliminary prospectus supplement and the accompanying prospectus to the extent it is inconsistent with the information in such preliminary prospectus supplement or the accompanying prospectus.
    No PRIIPs key information document (KID) has been prepared as the securities described in this document are not intended to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area.
    3

    4
    Any disclaimers or other notices that may appear below are not applicable to this communication and should be disregarded. Such disclaimers or other notices were automatically generated as a result of this communication being sent via Bloomberg or another email system.
    4
    Get the next $BAX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAX

    DatePrice TargetRatingAnalyst
    10/31/2025Buy → Hold
    Argus
    8/4/2025$25.00Buy → Hold
    Stifel
    8/1/2025$25.00Buy → Neutral
    Goldman
    2/26/2025$42.00Buy
    Goldman
    2/24/2025Hold → Buy
    Argus
    2/20/2025$39.00Overweight
    Barclays
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    5/30/2024$36.00Neutral
    Goldman
    More analyst ratings

    $BAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Baxter downgraded by Argus

    Argus downgraded Baxter from Buy to Hold

    10/31/25 8:47:22 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Stifel with a new price target

    Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00

    8/4/25 8:18:58 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Goldman with a new price target

    Goldman downgraded Baxter from Buy to Neutral and set a new price target of $25.00

    8/1/25 8:11:11 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    SEC Filings

    View All

    SEC Form FWP filed by Baxter International Inc.

    FWP - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/19/25 5:17:33 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    11/19/25 4:21:24 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    11/19/25 9:03:26 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baxter Announces Increase in Maximum Tender Cap for 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Senior Unsecured Notes due 2027 (the "2027 Notes") that it can repurchase under its previously announced cash tender offer for the 2027 Notes (the "2027 Notes Tender Offer") from $300 million to $600 million, on the terms and subject to the conditions set forth in the related Offer to Purchase dated Nov. 19, 2025 (the "Offer to Purchase"). The terms of the previously announced cash tender offer by Baxter for its 2.600% Senior Unsecured Notes due 2026 (the "2026 Notes Tender Offer" and, togethe

    11/19/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Announces Tender Offers for 2026 Notes and 2027 Notes

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the commencement of tender offers, subject to the terms and conditions described below, to purchase for cash the debt securities issued by Baxter listed in the table below (collectively, the "Securities" and each a "series"). Subject to market conditions, the tender offers are expected to be funded using a portion of the proceeds from a concurrent offering of senior unsecured notes by the Company (the "New Notes"). The Company intends to use the remaining proceeds from the concurrent public offering of the New Notes to repay other indebtedness, including any remaining 2026 Notes and its outstanding term loan cr

    11/19/25 8:54:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Declares Quarterly Dividend

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on Jan. 2, 2026, to stockholders of record as of Nov. 28, 2025. The indicated annual dividend rate equates to $0.04 per share of common stock. "As we previously announced in conjunction with third-quarter 2025 earnings, we will be reducing the quarterly dividend beginning in January 2026," said Joel Grade, Baxter's executive vice president and chief financial officer. "This action is expected to free up more than $300 million in annual cash flow, consistent with our prior commitments an

    11/11/25 4:30:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP,Group President,Pharma Sonig Alok covered exercise/tax liability with 3,191 shares, decreasing direct ownership by 2% to 128,219 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    9/4/25 6:02:32 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    President and CEO Hider Andrew P. was granted 368,050 shares (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    9/4/25 6:01:54 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    EVP and CFO Grade Joel T. was granted 102,712 shares, increasing direct ownership by 86% to 222,560 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    9/4/25 6:01:18 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Leadership Updates

    Live Leadership Updates

    View All

    Baxter Appoints Andrew Hider Chief Executive Officer

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Amerant Bancorp Announces Appointment of Two New Board Members

    Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe

    6/24/25 9:20:00 AM ET
    $AMTB
    $BAX
    $WBS
    Major Banks
    Finance
    Medical/Dental Instruments
    Health Care

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    $BAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Baxter International Inc. (Amendment)

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 5:00:53 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Baxter International Inc.

    SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 1:08:57 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Financials

    Live finance-specific insights

    View All

    Baxter Announces Increase in Maximum Tender Cap for 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Senior Unsecured Notes due 2027 (the "2027 Notes") that it can repurchase under its previously announced cash tender offer for the 2027 Notes (the "2027 Notes Tender Offer") from $300 million to $600 million, on the terms and subject to the conditions set forth in the related Offer to Purchase dated Nov. 19, 2025 (the "Offer to Purchase"). The terms of the previously announced cash tender offer by Baxter for its 2.600% Senior Unsecured Notes due 2026 (the "2026 Notes Tender Offer" and, togethe

    11/19/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Declares Quarterly Dividend

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on Jan. 2, 2026, to stockholders of record as of Nov. 28, 2025. The indicated annual dividend rate equates to $0.04 per share of common stock. "As we previously announced in conjunction with third-quarter 2025 earnings, we will be reducing the quarterly dividend beginning in January 2026," said Joel Grade, Baxter's executive vice president and chief financial officer. "This action is expected to free up more than $300 million in annual cash flow, consistent with our prior commitments an

    11/11/25 4:30:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Reports Third-Quarter 2025 Results

    Third-quarter sales from continuing operations of $2.84 billion increased 5% on a reported basis and 2% on an operational basis1,2 Third-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.10); adjusted diluted EPS from continuing operations of $0.69 Andrew Hider joined the company as president and chief executive officer (CEO), now leading the company's focus to drive continuous improvement and sustainable growth and create shareholder value Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2025. "I joined Baxter because it's a global healthcare leader – an iconic brand with an

    10/30/25 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care